Xenetic Biosciences, Inc. (XBIO)

NCM – Цена в реальном времени. Валюта: USD

3.02

-0.12 (-3.68%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.02

-0.01 (-0.25%)

После закрытия: May 12, 2026, 4:27 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Xenetic Biosciences, Inc. (XBIO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Видео

No Data

Пресс-релизы

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Search stocks

Xenetic Biosciences, Inc. (XBIO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Видео

No Data

Пресс-релизы

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform